Controlling Chaos in Oncology Testing
|
|
- Lewis Payne
- 5 years ago
- Views:
Transcription
1 HORIZON DISCOVERY Controlling Chaos in Oncology Testing 16 th March 2016 Brian Burke PhD
2 Disclaimer This Presentation does not constitute or form any part of an offer to sell, or invitation to purchase or apply for or enter into any contract or make any other commitment whatsoever in relation to, securities. Although reasonable care has been taken to ensure that the facts stated in this Presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this Presentation have not been formally verified by Horizon Discovery plc (the Company ) or any other person. Accordingly, no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this Presentation and no reliance should be placed on such information or opinions. Further, the information in this Presentation is not complete and is subject to updating, revision, further verification and amendment. Neither the Company, nor any of its subsidiaries, nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this Presentation. Accordingly, information contained in the Presentation is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person or published in whole or in part, for any purpose. In particular, the distribution of this Presentation in certain jurisdictions may be restricted by law, and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of laws of any such jurisdiction. This Presentation includes certain forward-looking statements, estimates and projections with respect to the anticipated future performance of Horizon Discovery plc, its products and the markets in which it operates. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and such statements, estimates and projections reflect the various assumptions made by the Company which assumptions may or may not prove to be correct. These forward-looking statements speak only as at the date of this Presentation. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in the Presentation to reflect any change in the Company s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. No part of this Presentation, or the fact of its distribution, should form the basis of or be relied upon in connection with any contract or commitment or investment decision whatsoever. This Presentation does not constitute a recommendation regarding the securities of the Company. By participating in and/or accepting delivery of this Presentation you agree to be bound by the foregoing restrictions and the other terms of this disclaimer. 2
3 About Horizon Discovery Cell Line Builders Reference Standards 3
4 Value for money? Sensitivity? Data Analysis? Patient Safety THE PATIENT? Reimbursement Guidance and Proficiency Cost of Drug Development FDA CLIA CAP Pharma 4
5 Precision Medicine Development Pipeline Research & Development Assay Development Sample Screening Patient Stratification Clinical Studies Phase II & III CLIA Studies Patient Stratification On Market Companion Diagnostics Proficiency Testing/Ring Trials Acquisition of limited clinical samples Clinical Samples are heterogeneous and not quantitative Clinical Trial time lines and use of multiple partners/geographies can lead to drift in assay performance Outsourcing can make managing variation more difficult Unnecessary and sustained variability can affect Study performance New drugs rely on successful and effective adoption of diagnostics to ensure reimbursement Proficiency Testing benefits from samples that are quantitative and that permit preanalytical and analytical evaluation of diagnostic workflows CONFIDENTIAL 5 Research Use Only
6 Why are we here? Key Observations Assays are currently developed in silos There is no quick way to benchmark assays or platforms What makes a good assay in a development lab does not always translate In spite of the importance of diagnostics to Precision Medicine, they still remain an add on in many cases 6
7 WHY DO WE NEED REFERENCE STANDARDS?
8 Would you fly in a plane with an altimeter accurate to 10%? Heathrow 25m +/- 2.5m A Bumpy Landing Guangxi 690m +/- 69m Crash Landing 8848 m Tenzing 2860m +/- 286m Never Even Close!! 8
9 Percentage of Incorrect Results External Quality Assessment 40 EGFR Genotyping Errors External Quality Assessment EGFR Sample Tested Only 70% of laboratories passed the proficiency test. False -negatives and false-positives were the main sources of error. European Molecular Quality Network (EMQN) 9
10 Molecular Diagnostic Assay Biomarker Negative Biomarker False Negative No treatment No side-effects No treatment Shortened patients life Treatment with no benefit Patient suffers side-effects Biomarker False Positive Treatment Extended patients life Biomarker Positive As we push the limits of technology, the risk of false results will increase 10
11 Sources of Variability Tumour sample As lower allelic frequencies increase in clinical relevance, workflows become more fallible Reference Materials Action Analysis DNA extraction Variant Calling/ Confidence Scoring DNA Quantification Library Preparation Sequencing Alignment/Mapping 11
12 HOW DO WE BUILD REFERENCE STANDARDS?
13 Not All Controls are Created Equal! Horizon uses highly characterised cell lines to build reference standards This gives us highly defined building blocks to create reference standards which reflect the biology of the patient. Better still, these reference standards are consistent and evergreen! Horizon has developed manufacturing processes that allow for consistent, long term production of reference standards NORMAL CELL NORMAL CELLS MUTANT CELLS SINGLE MUTATION Products Services Drugs MUTATED CELL PATIENT IN A TEST TUBE 13
14 Formats available PRE-ANALYTIC ANALYTIC cfdna Representative genomic DNA fragmented to bp Validated allelic frequencies to 0.01% Genomic DNA Precise allelic frequencies from % Extensively validated 50ng/μl FFPE Precise allelic frequencies from % Validated quantities of DNA in FFPE FFPE IHC Validated by Quantitative Digital Pathology (QDP) Quantified levels of protein expression (low to high) Formalin Compromised DNA Three tiers of formalin treatment: low, medium and high Validated by Tapescreen assay Multiplex DNA for NGS Multiple mutations in a single sample Extensively validated 50ng/μl FFPE FISH Hard-to-source biomarkers available Renewable source of positive and negative cells FFPE RNA Hard-to-source biomarkers available Consistent and reproducible 14
15 Covering all Diagnostic Modalities NGS Oncology Panels Q-Seq Coverage of TruSeq, AmpliSeq, and more Real Time PCR EGFR, KRAS, BRAF Exomes Genome in a Bottle Immuno-Oncology PD-L1 Liquid Biopsies Cell free DNA Reference Standards RNAseq NEW NSCLC Fusion Control. 15
16 NEXT GENERATION SEQUENCING
17 NGS: Massive Opportunity vs Massive Variability Accuracy ranked highest in importance for users of next-generation sequencing systems. NOTE: Based on a survey of 108 end users. SOURCE: Frost & Sullivan 17
18 One Sample Three Platforms - 80% Agreement # SNPs (% of SNPs detected) Platform #1 Platform #2 Platform #3 SOURCE: GIAB Slides
19 One Data Set Five Bioinformatic Workflows - 60% Agreement O Rawe et al. Genome Medicine 2013, 5:28 SOURCE: GIAB Slides
20 Horizon NGS Philosophy Deployment NGS technology is one of the key advances in the diagnostic space, promising greater breadth of data with more tangible pricing points HDx led the adoption of a more direct approach to assessing the performance of NGS platforms in the oncology space HDx enables key variables such as allele frequency, effects of formalin or genotype specific effects to be investigated directly Horizon is now extending this to structural variants and increasing customization around formalin 20
21 Multi-Gene Multiplex Case Study for IonTorrent / Ampliseq gdna Source: Horizon Discovery Partner A Partner B Partner C Partner D Horizon Discovery Partner D FFPE Platform: QX100 Droplet Digital PCR System AmpliSeq Cancer Panel Ampliseq Cancer Hotspot Panel v2 Ampliseq Cancer Hotspot Panel v2 (Average of 8 runs) Ampliseq Panel QX100 Droplet Digital PCR System Ampliseq Sequencing Depth N/A x Average 5000x 2000X N/A Gene Mutation Expected Observed mutant ratio Observed mutant ratio BRAF V600E KIT D816V EGFR ΔE746 - A Not detected Not detected EGFR L858R EGFR T790M Not detected Not detected EGFR G719S KRAS G13D KRAS G12D Not detected NRAS Q61K PIK3CA H1047R PIK3CA E545K Difficulty in detecting the lower allelic frequencies in FFPE sample 21
22 Case Study Data for Tru-Q NGS Reference Standards 5% blend 2.5% blend 1.3% blend Gene Source: Platform: Mutation Horizon Diagnostics Predicted % N/A Horizon Diagnostics Observed % QX100 Droplet Digital PCR System Partner Ion Torrent BRAF V600M EGFR T790M EGFR L858R EGFR L861Q KIT D816V KRAS G12A KRAS G12R NRAS Q61K Horizon Diagnostics Predicted % N/A Horizon Diagnostics Observed % QX100 Droplet Digital PCR System Partner Ion Torrent Horizon Diagnostics Predicted % N/A Horizon Diagnostics Observed % QX100 Droplet Digital PCR System Partner Ion Torrent missing missing missing missing missing missing Specific and Sensitive down to 5% allelic frequency Specific and Sensitive down to 2.5% allelic frequency Not sensitive to detect down to 1% for all variants 22
23 Clinical Validation Using Horizon s NGS Process Standard Case Study: CLIA Validation of AltheaDx Oncology Panel 150 (AOP 150) using HDx Reference Standards Concordance with dpcr, average six IonTorrent PGM NGS runs 23
24 Routine Assay Monitoring Results from a commercially-available NGS-based Oncology Panel evaluated using Horizon s Quantitative Multiplex Reference Standard (QMRS) in FFPE format; collected over a period of 8 months. 24
25 MOVING AWAY FROM THE INVASIVE
26 ctdna Low Copy Number Reference Standard Five Mutant Multiplex in six formats developed containing all the following EGFR mutations: T790M L861Q G719S L858R ΔE746- A750 Six multiplex reference standards defined by copy number: Mutant copies in 5,000 total EGFR copies (0.5% Mutant Allele Burden) Mutant copies in 50,000 total EGFR copies (0.05% Mutant Allele Burden) Mutant copies in 5,000 total EGFR copies (1.0% Mutant Allele Burden) Mutant copies in 50,000 total EGFR copies (0.1% Mutant Allele Burden) Mutant copies in 5,000 total EGFR copies (2.0% Mutant Allele Burden) Mutant copies in 50,000 total EGFR copies (0.2% Mutant Allele Burden) 26
27 ctdna Assay Verification Down to 0.05% Allelic Frequency 25 Mutant copies in 50,000 total EGFR copies EGFR Multiplex #1 #2 Wild Type Effective mutant allele frequency 0.5% 0.05% 0% Expected Observed Expected Observed Expected Observed ΔE746-A Mutant Copies per 5000 Total Copies G719S L858R L861Q T790M Concentration (Total Copies EGFR per µl) Manufacturing performance is excellent in spite of limitations of some probe sets 27
28 Fragmented K-Ras and N-Ras Reference Standards Gene Mutation Allelic Frequency K-Ras G12C 50% 5% 1% 0.1% N-Ras Q61K 50% 5% 1% 0.1% K-Ras G12C N-Ras Q61K WT 50% 5% 1% 0.1% 50% 5% 1% 0.1% 28
29 Assay development and validation Fragmented Multiplex Reference Standards Multiplex 1 Multiplex 2 Gene Mutation Allelic Frequency EGFR L861Q 7.1% K-Ras G12C 10% N-Ras A146T 10% PI3K3CA E545K 10%% Gene Mutation Allelic Frequency EGFR % EGFR T790M 7.7% N-Ras G12D 10% N-Ras Q61K 10% N-Ras K117N 10% 29 29
30 Fragmented K-Ras and N-Ras Reference Standards Gene Mutation Allelic Frequency K-Ras G12C 50% 5% 1% 0.1% N-Ras Q61K 50% 5% 1% 0.1% 30
31 What do the cfdna Standards look like? Expected Allelic Frequency (AF%) Gene Variant 5% Multiplex I 1% Multiplex I 0.1% Multiplex I 100% WT Multiplex I EGFR L858R EGFR ΔE746 - A EGFR T790M EGFR V769 - D770insASV KRAS G12D NRAS Q61K NRAS A59T PIK3CA E545K
32 cfdna Reference Standards 5% - 0.1% 1% Multiplex I cfdna Reference Standard assessed using Droplet Digital PCR (blue), Ion Torrent (orange) and MiSeq (grey). All assays utilized amplicon-based enrichment. Figure 1: Example trace showing the fragment sizes collected by D1000 DNA ScreenTape assay, comparing cfdna HDx Reference Standards (Red and Green traces) to cfdna extracted from human plasma (Blue trace). cfdna from human plasma was provided by CareDx,Inc. Leftmost peaks-internal marker for the assay. Rightmost peaksfragmented materials. 32
33 HDx Reference Standards Every Assay, Every Run, Every Confidence MDx/NGS Labs Support workflow analysis and setup Provision of positive reference standard for everyday run control ISH Labs FISH and IHC applications External reference standard to ensure workflow integrity Universal across time, across platforms, across operators and across geographies 33
34 34
Analytical verification methods for the Oncomine Lung cfdna Assay using the Ion S5 XL System
WHITE PAPER Oncomine Lung cfdna Assay and Ion S5 XL System Analytical verification methods for the Oncomine Lung cfdna Assay using the Ion S5 XL System Key highlights Investigate tumor heterogeneity and
More informationEnterprise Interest I am an employee of ThermoFisher Scientific.
Enterprise Interest I am an employee of ThermoFisher Scientific. Developing a multiplex next-generation sequencing assay to study highly clonal tumor samples Dumitru Brinza, Ph.D Clinical Next-Generation
More informationDetection of Rare Variants in Degraded FFPE Samples Using the HaloPlex Target Enrichment System
Detection of Rare Variants in Degraded FFPE Samples Using the HaloPlex Target Enrichment System Application Note Author Linus Forsmark Henrik Johansson Agilent Technologies Inc. Santa Clara, CA USA Abstract
More informationAccessing advanced TIDVAL technology at cost in return for sharing the up-side
HORIZON DISCOVERY Accessing advanced TIDVAL technology at cost in return for sharing the up-side On Helix, Cambridge UK, July 2015 Jon Moore CSO Disclaimer This Presentation does not constitute or form
More informationFunctional DNA Quality Analysis Improves the Accuracy of Next Generation Sequencing from Clinical Specimens
Functional DNA Quality Analysis Improves the Accuracy of Next Generation Sequencing from Clinical Specimens Overview We have developed a novel QC, the SuraSeq DNA Quantitative Functional Index (QFI ).
More informationA new paradigm in testing for NSCLC-targeted therapies
A new paradigm in testing for NSCLC-targeted therapies Accelerate results, from sample to report, with the first IVD NGS-based test NEW Oncomine Dx Target Test The Ion Torrent Oncomine Dx Target Test is
More informationAccessible answers. Targeted sequencing: accelerating and amplifying answers for oncology research
Accessible answers Targeted sequencing: accelerating and amplifying answers for oncology research Help advance precision medicine Accelerate results with Ion Torrent NGS Life without cancer. This is our
More informationEvaluation of Restriction Enzymes for the Analysis of Circulating Free DNA by Droplet Digital PCR
Evaluation of Restriction Enzymes for the Analysis of Circulating Free DNA by Droplet Digital PCR Amanda Weaver Cancer Genomics Consortium 2017 Summer Meeting August 7, 2017 Acknowledgements Everyone at
More informationMutation analysis in cell-free DNA from cancer patients
Mutation analysis in cell-free DNA from cancer patients dr. Anneleen Beckers project manager & product manager at Biogazelle CRIG s digital PCR mini-symposium, May 15, 2018 2018 Biogazelle. All rights
More informationHighly Sensitive, Multiplexed ctdna Mutation Detection on MassARRAY :
Highly Sensitive, Multiplexed ctdna Mutation Detection on MassARRAY : Lung & Colon Cancer Panel Pre-Launch & Data Sharing 栾晓辉, Ph.D. Senior Scientist, Application Development Agena Bioscience, Greater
More informationDiagnostics in Oncology Mark Kockx MD, PhD
HistoGeneX The Real World A Specialized of companion Biomarker & Integrated Pathology Laboratory Diagnostics in Oncology Mark Kockx MD, PhD 1 2 HistoGeneX located in Antwerp, Belgium and Chicago, Illinois
More informationImplementation of Ion AmpliSeq in molecular diagnostics
Implementation of Ion AmpliSeq in molecular diagnostics The Rotterdam Experience Ronald van Marion Deelnemersbijeenkomst SKML sectie Pathologie Amersfoort, 26 mei 2016 Molecular Diagnostics in Rotterdam
More informationSample to Insight. Dr. Bhagyashree S. Birla NGS Field Application Scientist
Dr. Bhagyashree S. Birla NGS Field Application Scientist bhagyashree.birla@qiagen.com NGS spans a broad range of applications DNA Applications Human ID Liquid biopsy Biomarker discovery Inherited and somatic
More informationTitelstijl van model bewerken
Generate Titelstijl van and verify model your bewerken data Solutions for all your genetic analysis needs Sanger Sequencing Microarray technology QuantStudio real-time and digital PCR Ion Torrent NGS systems
More informationYour Best Data: Teaming QIAGEN Chemistry & Bioinformatics to Drive Samples to Insight
Your Best Data: Teaming QIAGEN Chemistry & Bioinformatics to Drive Samples to Insight Aysel Heckel Director Clinical Solutions Sales Dr. Anne Arens Field Application Scientist Course on Variant Detection
More informationTargeted Sequencing in the NBS Laboratory
Targeted Sequencing in the NBS Laboratory Christopher Greene, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Gene Sequencing in Public Health Newborn Screening February
More informationIon S5 and Ion S5 XL Systems
Ion S5 and Ion S5 XL Systems Targeted sequencing has never been simpler Explore the Ion S5 and Ion S5 XL Systems Adopting next-generation sequencing (NGS) in your lab is now simpler than ever The Ion S5
More informationIon S5 and Ion S5 XL Systems
Ion S5 and Ion S5 XL Systems Targeted sequencing has never been simpler Explore the Ion S5 and Ion S5 XL Systems Adopting next-generation sequencing (NGS) in your lab is now simpler than ever The Ion S5
More informationKAPA hgdna QUANTIFICATION AND QC KIT:
Poster Note As presented at AGBT 2015, Marco Island, FL KAPA hgdna QUANTIFICATION AND QC KIT: The KAPA Human Genomic DNA Quantification and QC Kit Enables Prediction of Sequencing Performance through User-Defined
More informationAssay Validation Services
Overview PierianDx s assay validation services bring clinical genomic tests to market more rapidly through experimental design, sample requirements, analytical pipeline optimization, and criteria tuning.
More informationPersonalized CAR-T Immunotherapy Platform
GLP, GMP, and CLIA-Certified Lab Personalized CAR-T Immunotherapy Platform Accelerate your cancer research and drug discovery Platform Overview 1500 Existing Hybridomas and Antibody Engineering Custom
More informationCorporate Presentation. September 6th, 2018
Corporate Presentation September 6th, 2018 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than
More informationReference methods and materials for KRAS mutations in cell free DNA
Reference methods and materials for KRAS mutations in cell free DNA Alison Devonshire Molecular and Cell Biology team, LGC JCTLM Members' and Stakeholders' Meeting 30 November -1 December 2015 BIPM, Sèvres
More informationPMDA Perspectives on Companion Diagnostics Development in Japan. Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA
PMDA Perspectives on Companion Diagnostics Development in Japan Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA 1 Disclaimer Content Slide The views and opinions expressed
More informationIntroducing QIAseq. Accelerate your NGS performance through Sample to Insight solutions. Sample to Insight
Introducing QIAseq Accelerate your NGS performance through Sample to Insight solutions Sample to Insight From Sample to Insight let QIAGEN enhance your NGS-based research High-throughput next-generation
More informationHybridization,Approaches,to,Rare,Sequence, Variant,Detection,in,Human,DNA
Hybridization,Approaches,to,Rare,Sequence, Variant,Detection,in,Human,DNA David Yu Zhang Nov 2, 215 Rice University Conflict,of,Interest,Disclosures Research Collaboration: Leadership: searna Early detection
More informationStart With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development. Paul Docherty PhD Relationship Management
Start With the End in Mind A Diagnostic Company s Perspective on Companion Diagnostic Development Paul Docherty PhD Relationship Management Disclaimer This presentation contains my personal views and research
More informationQIAGEN s NGS Solutions for Biomarkers NGS & Bioinformatics team QIAGEN (Suzhou) Translational Medicine Co.,Ltd
QIAGEN s NGS Solutions for Biomarkers NGS & Bioinformatics team QIAGEN (Suzhou) Translational Medicine Co.,Ltd 1 Our current NGS & Bioinformatics Platform 2 Our NGS workflow and applications 3 QIAGEN s
More informationCAPTURE-BASED APPROACH FOR COMPREHENSIVE DETECTION OF IMPORTANT ALTERATIONS
CAPTURE-BASE APPROACH FOR COMPREHENSIVE ETECTION OF IMPORTANT ALTERATIONS SEQUENCE MUTATIONS MICROSATELLITE INSTABILITY AMPLIFICATIONS GENOMIC REARRANGEMENTS For Research Use Only. Not for iagnostic Purposes.
More informationNext Generation Oncology Sequencing in your Laboratory. Built by pioneers in cancer genomics and liquid biopsy approaches PROGENEUS
PROGENEUS Next Generation Oncology Sequencing in your Laboratory Built by pioneers in cancer genomics and liquid biopsy approaches For Research Use Only. Not for iagnostic Purposes. personalgenome.com/progeneus
More informationAbcam Plc. JP Morgan Healthcare Conference January 2017
Abcam Plc JP Morgan Healthcare Conference January 2017 2 Disclaimer Important information The information provided in this presentation is for the sole use of those attending the presentation; it shall
More informationPrecipio, Inc. Instructions for Use. PIK3CA Exon 9 Mutation Analysis using ICE COLD-PCR for Detection with High Resolution Melting
Precipio, Inc. Instructions for Use PIK3CA Exon 9 Mutation Analysis using ICE COLD-PCR for Detection with High Resolution Melting Table of Contents Manufacturer 2 Reagent Preparation 2 Kit Components and
More informationAlmac Diagnostics. NGS Panels: From Patient Selection to CDx. Dr Katarina Wikstrom Head of US Operations Almac Diagnostics
Almac Diagnostics NGS Panels: From Patient Selection to CDx Dr Katarina Wikstrom Head of US Operations Almac Diagnostics Overview Almac Diagnostics Overview Benefits and Challenges of NGS Panels for Subject
More informationCHARTING THE COURSE FOR PRECISION MEDICINE
A Friends of Cancer Research White Paper CHARTING THE COURSE FOR PRECISION MEDICINE ADOPTING CONSENSUS ANALYTICAL STANDARDS AND STREAMLINING APPROVAL PATHWAYS FOR POST-MARKET MODIFICATIONS FOR NGS TESTS
More informationGoing further with 3-color Crystal Digital PCR: characterizing CNV and indels. 4th qpcr & Digital PCR Congress 09/13/2018
Going further with 3-color Crystal Digital PCR: characterizing CNV and indels 4th qpcr & Digital PCR Congress 09/13/2018 Overview of presentation I. Introduction to digital PCR and Naica System II. Reliable
More informationRegulatory Perspectives on NGS-based CDx
14 th DIA Japan Annual Meeting 2017 November 12-14, 2017 Tokyo Big Sight Ariake Regulatory Perspectives on NGS-based CDx Reiko Yanagihara, Ph.D. Office of In Vitro Diagnostics Deputy Review Director Pharmaceuticals
More informationThe EORTC Molecular Screening programme SPECTA
The EORTC Molecular Screening programme SPECTA February 2016 Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium The changing shape of clinical research Phase I RESOURCES Phase III The changing
More informationAnalytics Behind Genomic Testing
A Quick Guide to the Analytics Behind Genomic Testing Elaine Gee, PhD Director, Bioinformatics ARUP Laboratories 1 Learning Objectives Catalogue various types of bioinformatics analyses that support clinical
More informationGENOMICS WORKFLOW SOLUTIONS THAT GO WHERE THE SCIENCE LEADS. Genomics Solutions Portfolio
GENOMICS WORKFLOW SOLUTIONS THAT GO WHERE THE SCIENCE LEADS Genomics Solutions Portfolio WORKFLOW SOLUTIONS FROM EXTRACTION TO ANALYSIS Application-based answers for every step of your workflow Scientists
More informationDisclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
More informationFrom Liquid Biopsy and FFPE Samples to Results
From Liquid Biopsy and FFPE Samples to Results Fully automated purification, reliable quantification and bisulfite conversion of cell-free circulating DNA and DNA from FFPE samples Fully automated purification,
More informationGENOMICS WORKFLOW SOLUTIONS THAT GO WHERE THE SCIENCE LEADS. Genomics Solutions Portfolio
GENOMICS WORKFLOW SOLUTIONS THAT GO WHERE THE SCIENCE LEADS Genomics Solutions Portfolio WORKFLOW SOLUTIONS FROM EXTRACTION TO ANALYSIS Application-based answers for every step of your workflow Scientists
More informationDevelopment of quantitative targeted RNA-seq methodology for use in differential gene expression
Development of quantitative targeted RNA-seq methodology for use in differential gene expression Dr. Jens Winter, Market Development Group Biological Biological Research Content EMEA QIAGEN Universal Workflows
More informationFrom Liquid Biopsy and FFPE Samples to Results
www.autogen.com 774-233-3000 From Liquid Biopsy and FFPE Samples to Results Fully automated purification, reliable quantification and bisulfite conversion of cell-free circulating DNA and DNA from FFPE
More informationDeveloping an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL
Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL James Storhoff, Ph.D. Senior Manager, Diagnostic Test Development World Cdx, Boston, Sep. 10th Molecules That
More informationACCEL-NGS 2S DNA LIBRARY KITS
ACCEL-NGS 2S DNA LIBRARY KITS Accel-NGS 2S DNA Library Kits produce high quality libraries with an all-inclusive, easy-to-use format. The kits contain all reagents necessary to build high complexity libraries
More informationThe MiniSeq System. Explore the possibilities. Discover demonstrated NGS workflows for molecular biology applications.
The MiniSeq System. Explore the possibilities. Discover demonstrated NGS workflows for molecular biology applications. Let your work flow with Illumina NGS. The MiniSeq System delivers powerful and cost-effective
More informationGet to Know Your DNA. Every Single Fragment.
HaloPlex HS NGS Target Enrichment System Get to Know Your DNA. Every Single Fragment. High sensitivity detection of rare variants using molecular barcodes How Does Molecular Barcoding Work? HaloPlex HS
More informationHaloPlex HS. Get to Know Your DNA. Every Single Fragment. Kevin Poon, Ph.D.
HaloPlex HS Get to Know Your DNA. Every Single Fragment. Kevin Poon, Ph.D. Sr. Global Product Manager Diagnostics & Genomics Group Agilent Technologies For Research Use Only. Not for Use in Diagnostic
More informationWELCOME. Norma J. Nowak, PhD Executive Director, NY State Center of Excellence in Bioinformatics and Life Sciences (CBLS)
WELCOME Norma J. Nowak, PhD Executive Director, NY State Center of Excellence in Bioinformatics and Life Sciences (CBLS) Director, UB Genomics and Bioinformatics Core (GBC) o o o o o o o o o o o o Grow
More informationFirst Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
More informationPlasma EGFR T790M ctdna status is associated with clinical outcome in. advanced NSCLC patients with acquired EGFR-TKI resistance
Plasma EGFR T790M ctdna status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance 1# D Zheng; 2# X Ye; 3 MZ Zhang; 2 Y Sun; 1 JY Wang; 1 J Ni; 1 HP Zhang;
More informationQuantStudio 3D Digital PCR System
PRODUCT BULLETIN QuantStudio 3D Digital PCR System QuantStudio 3D Digital PCR System Absolutely attainable digital PCR Simple chip-based workflow no emulsion PCR Affordable low total cost of ownership
More informationLiquidBiopsy LIQUIDBIOPSY. Automated Rare Template Isolation Platform
LiquidBiopsy LIQUIDBIOPSY Automated Rare Template Isolation Platform Enabling cancer research with highly multiplexed molecular analysis of serially collected blood samples The LiquidBiopsy Platform simplifies
More informationA Crash Course in NGS for GI Pathologists. Sandra O Toole
A Crash Course in NGS for GI Pathologists Sandra O Toole The Sanger Technique First generation sequencing Uses dideoxynucleotides (dideoxyadenine, dideoxyguanine, etc) These are molecules that resemble
More informationDigital DNA/RNA sequencing enables highly accurate and sensitive biomarker detection and quantification
Digital DNA/RNA sequencing enables highly accurate and sensitive biomarker detection and quantification Erwin Chen ( 陳立德 ) Technical Product Specialist QIAGEN Taiwan Precision medicine: Right drug, right
More informationProduct selection guide Ion GeneStudio S5 Series
Cancer genomics research Molecular profiling Ion AmpliSeq Comprehensive Cancer Panel Cat. No. 4477685 Ion AmpliSeq Made-to-Order Panels (Customize your own or browse redesigned community panels at ampliseq.com)
More informationTHE WHITE HOUSE Office of the Vice President
FOR IMMEDIATE RELEASE October 17, 2016 THE WHITE HOUSE Office of the Vice President FACT SHEET: Vice President Biden Delivers Cancer Moonshot Report, Announces Public and Private Sector Actions to Advance
More informationEnsuring Translational Scientific Understanding Underpins Your Biomarker-Dx Strategy. Thomas Krahn Bayer Pharma AG
Ensuring Translational Scientific Understanding Underpins Your Biomarker-Dx Strategy Thomas Krahn Bayer Pharma AG Forward-Looking Statements / Disclosures This presentation may contain forward-looking
More informationClinical Molecular Biology A Danish Perspective
Clinical Molecular Biology A Danish Perspective Niels Pallisgaard Molecular biologist Clinical Biochemistry, Vejle Sygehus niels.pallisgaard@slb.regionsyddanmark.dk Here s my DNA sequence The Epidermal
More informationDetect low-level somatic mutations in FFPE samples using an extended RAS research assay
APPLICATION NOTE SeqStudio and 3500/3500xL Genetic Analyzers Detect low-level somatic mutations in FFPE samples using an extended RAS research assay Optimized performance using Sanger sequencing In this
More informationGENOTYPING-BY-SEQUENCING USING CUSTOM ION AMPLISEQ TECHNOLOGY AS A TOOL FOR GENOMIC SELECTION IN ATLANTIC SALMON
GENOTYPING-BY-SEQUENCING USING CUSTOM ION AMPLISEQ TECHNOLOGY AS A TOOL FOR GENOMIC SELECTION IN ATLANTIC SALMON Matthew Baranski, Casey Jowdy, Hooman Moghadam, Ashie Norris, Håvard Bakke, Anna Sonesson,
More informationCorporate Presentation. February 2, 2018
Corporate Presentation February 2, 2018 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements
More informationApplications of the Ion AmpliSeq Immune Repertoire Assay Plus TCRβ
Applications of the Ion AmpliSeq Immune Repertoire Assay Plus TCRβ Timothy Looney, PhD Staff Scientist, Clinical Next-Generation Sequencing Division Thermo Fisher Scientific The world leader in serving
More informationProduct selection guide Ion S5 and Ion S5 XL Systems
Product selection guide Ion S5 and s Cancer genomics research Molecular profiling Ion AmpliSeq Ready-to-Use Panels Ion AmpliSeq Comprehensive Cancer Panel Cat. No. 4477685 Ion AmpliSeq Made-to-Order Panels
More informationSummary of key processes for tumor BRCA testing. Q&A Session Hadassah Medical Center, Jerusalem Sabine Merkelbach-Bruse
Summary of key processes for tumor BRCA testing Q&A Session 29.01.2018 Hadassah Medical Center, Jerusalem Sabine Merkelbach-Bruse Review of key processes Overview Summary of key processes Quality assurance
More informationSureSelect XT HS. Target Enrichment
SureSelect XT HS Target Enrichment What Is It? SureSelect XT HS joins the SureSelect library preparation reagent family as Agilent s highest sensitivity hybrid capture-based library prep and target enrichment
More informationresequencing storage SNP ncrna metagenomics private trio de novo exome ncrna RNA DNA bioinformatics RNA-seq comparative genomics
RNA Sequencing T TM variation genetics validation SNP ncrna metagenomics private trio de novo exome mendelian ChIP-seq RNA DNA bioinformatics custom target high-throughput resequencing storage ncrna comparative
More information2018 RW Baird Health Care Conference. September 5 th, 2018
2018 RW Baird Health Care Conference September 5 th, 2018 1 Forward-looking Statements This presentation and the accompanying oral commentary contain forward -looking statements that involve risks, uncertainties
More informationMedical Devices; Immunology and Microbiology Devices; Classification of the Next Generation
This document is scheduled to be published in the Federal Register on 06/22/2018 and available online at https://federalregister.gov/d/2018-13406, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationPrecipio, Inc. Instructions for Use. EGFR Exon 12 Mutation Enrichment using ICE COLD-PCR
Precipio, Inc. Instructions for Use EGFR Exon 12 Mutation Enrichment using ICE COLD-PCR Table of Contents Manufacturer 2 Intended Use 2 Reagent Preparation 2 Kit Components and Storage Conditions 2 Optional
More informationDNA. Clinical Trials. Research RNA. Custom. Reports CLIA CAP GCP. Tumor Genomic Profiling Services for Clinical Trials
Tumor Genomic Profiling Services for Clinical Trials Custom Reports DNA RNA Focused Gene Sets Clinical Trials Accuracy and Content Enhanced NGS Sequencing Extended Panel, Exomes, Transcriptomes Research
More informationMolecular Diagnosis Challenges & Solutions. Using Molecular Kits or Laboratory Developed Tests (Home Brew), Emphasis on Validation
Using Molecular Kits or Laboratory Developed Tests (Home Brew), Emphasis on Validation Molecular Diagnosis Challenges & Solutions Behzad Poopak, DCLS PhD Tehran Medical Branch- Islamic Azad University
More informationPrecipio, Inc. Instructions for Use. EGFR Exon 18 Mutation Enrichment using ICE COLD-PCR
Precipio, Inc. Instructions for Use EGFR Exon 18 Mutation Enrichment using ICE COLD-PCR Table of Contents Manufacturer 2 Intended Use 2 Reagent Preparation 2 Kit Components and Storage Conditions 2 Optional
More informationUniquely positioned for the future. Severin Schwan, CEO Roche Group Merrill Lynch, London, 16 September 2008
Uniquely positioned for the future Severin Schwan, CEO Roche Group Merrill Lynch, London, 16 September 2008 1 This presentation contains certain forward-looking statements. These forward-looking statements
More informationRoche Sequencing Solutions CHANGING SCIENCE CHANGING LIVES
Roche Sequencing Solutions CHANGING SCIENCE CHANGING LIVES Roche Sequencing Solutions Roche is helping to shape the future of personalized medicine by integrating best-in-class sequencing technologies
More informationA Blueprint for Drug/Diagnostic Co-Development: Next-Generation Sequencing (NGS) in Oncology. September 2014
FOCR-NGS-Report-115_1 2/17/15 10:04 AM Page 1 A Blueprint for Drug/Diagnostic Co-Development: Next-Generation Sequencing (NGS) in Oncology September 2014 FOCR-NGS-Report-115_1 2/17/15 10:04 AM Page 2 TABLE
More informationIMGM Laboratories GmbH. Sales Manager
IMGM Laboratories GmbH Dr. Jennifer K. Kuhn Sales Manager About IMGM Laboratories IMGM Laboratories was founded in 2001 IMGM operates as professional provider of advanced genomic services from research
More informationPrecipio, Inc. Instructions for Use. BRAF Exon 15 Mutation Enrichment using ICE COLD-PCR
Precipio, Inc. Instructions for Use BRAF Exon 15 Mutation Enrichment using ICE COLD-PCR Table of Contents Manufacturer 2 Intended Use 2 Reagent Preparation 2 Kit Components and Storage Conditions 2 ICE
More informationWhole Genome Sequencing in Cancer Diagnostics (research) Nederlandse Pathologiedagen 19 & 20 November 2015
Whole Genome Sequencing in Cancer Diagnostics (research) Nederlandse Pathologiedagen 19 & 20 November 2015 Dr. I.J. Nijman Disclosure slide (Potential) conflict of interest None For this meeting relevant
More informationWelcome to the NGS webinar series
Welcome to the NGS webinar series Webinar 1 NGS: Introduction to technology, and applications NGS Technology Webinar 2 Targeted NGS for Cancer Research NGS in cancer Webinar 3 NGS: Data analysis for genetic
More informationTranslating Droplet Digital PCR into Clinical Use. Christopher Campbell West Midlands Regional Genetics Laboratory
Translating Droplet Digital PCR into Clinical Use Christopher Campbell West Midlands Regional Genetics Laboratory Introduction to digital PCR Applications in the West Midlands Regional Genetics Laboratory
More informationPushing the Leading Edge in Protein Quantitation: Integrated, Precise, and Reproducible Protein Quantitation Workflow Solutions
2017 Metabolomics Seminars Pushing the Leading Edge in Protein Quantitation: Integrated, Precise, and Reproducible Protein Quantitation Workflow Solutions The world leader in serving science 2 3 Cancer
More informationQIAseq SPE technology for Illumina : Redefining amplicon sequencing
Application Note QIAseq SPE technology for Illumina : Redefining amplicon sequencing Amplicon-based enrichment and sequencing takes advantage of PCR workflows to turn amplicons that represent regions of
More informationTECHNICAL SHEET IDYLLA KRAS MUTATION TEST
CE IVD TECHNICAL SHEET IDYLLA MUTATION TEST The Test, performed on the Biocartis system, is an in vitro diagnostic Test for the qualitative detection of 21 mutations in codons 12, 13, 59, 61, 117 and 146
More informationDNBseq TM SERVICE OVERVIEW Plant and Animal Whole Genome Re-Sequencing
TM SERVICE OVERVIEW Plant and Animal Whole Genome Re-Sequencing Plant and animal whole genome re-sequencing (WGRS) involves sequencing the entire genome of a plant or animal and comparing the sequence
More informationStrengthening the experience and embracing the shift
Strengthening the experience and embracing the shift THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES. IT IS SOLELY FOR USE AT A CAPITAL MARKETS EVENT AND IS PROVIDED
More informationPowering the Synthetic Biology and Genomics Revolutions
Powering the Synthetic Biology and Genomics Revolutions Advances in Genome Biology and Technology Marco Island, Florida February 28, 2019 Safe Harbor Statement This presentation contains forward-looking
More informationSingle Cell Genomics
Single Cell Genomics Application Cost Platform/Protocol Note 3 mrna-seq Cell capture/rt/library prep $1,990/Sample 10x Genomics Chromium 500-10,000 cells/sample 5 V(D)J + mrna Cell capture/rt/library prep
More informationUniquely positioned for the future
Uniquely positioned for the future Severin Schwan, CEO Roche Group Bellevue meets Management Seminar, January 09 1 This presentation contains certain forward-looking statements. These forward-looking statements
More informationPioneering Clinical Omics
Pioneering Clinical Omics Clinical Genomics Strand NGS An analysis tool for data generated by cutting-edge Next Generation Sequencing(NGS) instruments. Strand NGS enables read alignment and analysis of
More informationNRAS Mutation Analysis Reagents (Codons 12 and 13)
NRAS Mutation Analysis Reagents (Codons 12 and 13) User Manual V1.1 Cat No. GP18 32 reactions 1 CONTENTS Introduction 4 Overview of Mutector TM Assay 5 Materials Provided 6 Materials Required 7 Equipment
More informationAccurate Nucleic Acid Analysis is Critical to Successful Sequencing. Steve Siembieda VP Commercialization November 10, 2016
Accurate Nucleic Acid Analysis is Critical to Successful Sequencing Steve Siembieda VP Commercialization November 10, 2016 1 Advanced Analytical Privately-held instrumentation company, established in 1998
More informationComplete Success Begins with Sample Quality Control. Agilent 4150 and 4200 TapeStation Systems
Complete Success Begins with Sample Quality Control Agilent 4150 and 4200 TapeStation Systems Complete Success Begins with Sample Quality Control Agilent TapeStation systems are automated electrophoresis
More informationIon S5 and Ion S5 XL Systems
Ion S5 and Ion S5 XL Systems Targeted sequencing has never been simpler Introducing the Ion S5 and Ion S5 XL systems Now, adopting next-generation sequencing in your lab is simpler than ever. The Ion S5
More information227 AP and >100 CDx engagements
Anatomic pathology Q 2 Solutions comprehensive in-house end-to-end anatomic pathology and adjunct molecular services are designed to meet your clinical trial needs. Anatomic pathology is a vital part of
More informationAgilent NGS Solutions : Addressing Today s Challenges
Agilent NGS Solutions : Addressing Today s Challenges Charmian Cher, Ph.D Director, Global Marketing Programs 1 10 years of Next-Gen Sequencing 2003 Completion of the Human Genome Project 2004 Pyrosequencing
More informationSurely Better Target Enrichment from Sample to Sequencer
sureselect TARGET ENRICHMENT solutions Surely Better Target Enrichment from Sample to Sequencer Agilent s market leading SureSelect platform provides a complete portfolio of catalog to custom products,
More informationMulticolour Digital PCR for ctdna detection in breast cancer. Isaac Garcia-Murillas The Institute of Cancer Research, London
Multicolour Digital PCR for ctdna detection in breast cancer Isaac Garcia-Murillas The Institute of Cancer Research, London Breast cancer: a worldwide health issue Source: CRUK Progress in breast cancer
More informationNext Generation Sequencing (NGS) Market Size, Growth and Trends ( )
Next Generation Sequencing (NGS) Market Size, Growth and Trends (2014-2020) July, 2017 4 th edition Information contained in this market report is believed to be reliable at the time of publication. DeciBio
More information